Dominion Diagnostics offers a comprehensive single source solution for urine drug testing and routine clinical blood testing to support screening, diagnosis and monitoring.
Urine Drug Testing & Medication Monitoring
- State-of-the-art analytical methods for presumptive and definitive urine drug testing of parent drugs and/or metabolites
- An expanding test menu that supports a customized approach to patient-specific monitoring steered by medical necessity guidelines
- Industry-low detection limits to ensure scientifically sound insight into drug elimination and/or usage over time
Routine Clinical Blood Testing
- A robust menu of routine chemistry tests/panels, organ-specific and disease panels, hematology and microbiology testing
- Specialized logistics support, phlebotomy services and supplies to allow for specimen integrity
- 24-hour results to meet immediate screening, diagnosis and monitoring needs (in most cases)
An optimal combination of the top laboratory-based technologies produces accurate, clinically relevant results that support treatment.
Laboratory-Based Drug Monitoring
Enzyme Immunoassay (EIA)
EIA, used for the initial test in the analysis, is designed to detect the presence of multiple drugs and/or drug metabolites. EIA technology involves a specialized enzyme mixed with analyte-specific antibodies. If analyte (drug) is present in the specimen, an active enzyme will form generating a color change that can be measured on a spectrophotometric analyzer. The amount of enzyme formed is proportional to the amount of analyte present in the specimen. EIA provides only a preliminary analytical test result. A more specific alternative chemical method (e.g., UPLC-MS/MS) must be used to obtain a confirmed analytical result.
Enzyme Linked Immunosorbent Assay (ELISA)
ELISAs are microplate-based assays designed for the detection of either a specific analyte or group of compounds. Unlike an EIA, the ELISA requires a multi-step approach, where the key step requires immobilization of the target antigen. The assay itself can be performed with a number of modifications of the basic procedure including the use of a single or multiple capture antibodies to detect the antigen in a non-competitive manner. Alternatively, the ELISA can be performed as a competitive assay. The latter method is commonly used in commercially available ELISA kits.
Ultra Performance Liquid Chromatography/Tandem Mass Spectrometry (UPLC-MS/MS)
UPLC-MS/MS is a highly specific method used in the definitive identification of individual drug analytes. Compounds are analyzed by chromatographic separation (UPLC), followed by tandem mass spectrometry (MS/MS). With the addition of the UPLC component, the target compound(s) can be isolated from other sample components using specialized columns and solvents. This “pre-fractionated” sample is then introduced into the mass spectrometer, where it is ionized and fragmented. The detection and identification of specific analyte(s) is made based on the molecular characteristics (i.e., m/z) of both the precursor and product ions. By combining the physical separation capabilities of UPLC with the mass analysis and detection capabilities of tandem mass spectrometry, UPLC-MS/MS serves as the preferred method for the definitive identification and quantification of specific drugs and drug metabolites in biological samples.contact us for more information.
Routine Clinical Blood Testing
Dominion Diagnostics offers a full menu of routine blood testing services to support its urine drug testing and medication monitoring customers with a single source diagnostic solution.
Genetic Addiction Risk Testing and Pharmacogenetic Testing
Working with Geneus Health, Dominion Diagnostics offers two genetic testing solutions to support a personalized medicine approach to patient care.
Genetic Addiction Risk Score (GARS)®
From a simple cheek swab, GARS® is able to identify an individual’s genetic predisposition toward addictive, compulsive, impulsive behaviors, and personality disorders. These behaviors all share a common physiological root: an altered chemical balance in the brain, termed “Reward Deficiency Syndrome (RDS)”. GARS® looks at 4 Reward Deficiency Syndrome Behaviors and is designed to identify an individual's genetic predispositions to addictive and impulsive behaviors.
MyGenx® Pharmacogenetic Testing
MyGenx® is a proprietary pharmacogenetic panel covering 44 of the most common genes/SNPs causing genetic variation in medication effectiveness, 4 disease state predispositions, and provides information on anti-addictive drugs including Acamprosate (Campral), Disulfiram (Antabuse), Bupropion (Wellbutrin, Zyban, Aplenzin), Levodopa/Carbidopa (Sinemet), and Naltrexone (Vivitrol, Contrave).
Please contact us for more information.